Skip to content

The Potential Effect of Bitter Melon Supplementation in Pain Reduction Among Osteoarthritis Patients

The Potential Effect of Momordica Charantia (Bitter Melon) in Pain Reduction among Primary Knee Osteoarthritis Patients in Hospital Universiti Sains Malaysia

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/05/008649
Enrollment
76
Registered
2017-05-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Primary unilateral or bilateral knee osteoarthritis according to clinical and radiological criteria of the American college of Rheumatology (ACR).

Interventions

Intervention1: Momordica charantia (bitter melon): Momordica charantia (bitter melon) crude extract capsules (500mg). 3 capsules orally thrice daily post meal for 12 weeks. Control Intervention1: Plac

Sponsors

School of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1- Patients are within stable condition and willing to be involve in this study. 2- All patients with unilateral or bilateral knee osteoarthritis according to clinical and radiological criteria of the American college of Rheumatology (ACR). Knee pain and radiographic osteophytes plus at least one of three symptoms/signs listed below: -age more than 40 years OR -stiffness less than 30 minutes OR -crepitus. This criteria is widely accepted as the standard diagnosis criteria for knee OA with 91% sensitivity and 86% specificity. (Altman et al, 1986). 3- Have a radiological grade between I and III, as measured with the Kellgren-Lawrence method. Grade I: doubtful narrowing of joint space and possible osteophytic lipping. Grade II: defined osteophytes and possible narrowing of joint space. Grade III: Moderate multiple osteophytes, definite narrowing of joint space and some sclerosis and possible deformity of bone ends (Kellgren & Lawrence, 1957).

Exclusion criteria

Exclusion criteria: 1- Patients are within unstable condition and unwilling to be involve in this study. 2- Patient with secondary knee osteoarthritis, such as post traumatic OA, inflammatory arthritis, specifically rheumatoid arthritis, active gout (Giordano et al 2009). 3- Disabling co-morbid condition such as severe hematologic disorders, renal disease, liver disease, neoplasms, diabetes mellitus and other rheumatic diseases. (Giordano et al 2009) 4- Pregnancy or nursing. (Giordano et al 2009) 5- Patient with grade IV OA: Large osteophytes marked narrowing of joint space, severe sclerosis and definite deformity of bones ends. (Kellgren & Lawrence, 1957) 6- Patient with severe knee pain and willing for surgical intervention. 7- Those who had joint lavage, arthroscopy, or treatment with hyaluronic acid, or glucosamine during the previous 6 months. (Giordano et al 2009) 8- Patient who had been treated with intra-articular corticosteroids during the past 3 months. ( Giordano et al, 2009)

Design outcomes

Primary

MeasureTime frame
The Knee Injury and Osteoarthritis Outcome Score (KOOS)Timepoint: At baseline, every 4 weeks for 12 weeks

Secondary

MeasureTime frame
Inflammatory and metabolic profileTimepoint: At baseline and after supplementation completed (week 12)

Countries

Malaysia

Contacts

Public ContactDr Md Rizman Bin Md Lazin

Universiti Sains Malaysia

mdrizman@usm.my609-7676912

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026